{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:42:51Z","timestamp":1784875371817,"version":"3.55.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Quality and Outcomes"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Use of angiotensin-converting enzyme inhibitors (ACEIs)was associated with increased risk of lung cancer in a cohort study from the United Kingdom. We aimed to replicate these findings in a Danish population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a nested case-control study using data from 4 Danish national health and administrative registries. New users of ACEIs or angiotensin II receptor blockers in Denmark from January 1, 2000 were followed until December 31, 2015, incident lung cancer, death, or emigration. Each lung cancer case was matched with up to 20 controls on age, sex, duration of follow-up, and year of cohort entry using risk-set sampling. Conditional logistic regression was used to estimate odds ratios (ORs) for incident, histologically verified lung cancer with high use of ACEIs defined as a cumulative dose above 3650 defined daily doses. We examined different cumulative doses of ACEI (\u22641800, 1801\u20133650, &gt;3650 defined daily doses), examined whether the association varied with lung cancer histology, and repeated the analyses using thiazides as active comparator.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We included 9652 lung cancer cases matched to 190\u2009055 controls. High use of ACEIs was associated with lung cancer (adjusted OR, 1.33 [95% CI, 1.08\u20131.62]). Lower cumulative doses showed neutral associations (\u22641800 defined daily doses OR, 1.01 [95% CI, 0.94\u20131.09]; 1801\u20133650 defined daily doses OR, 1.03 [95% CI, 0.90\u20131.19]). CIs were wide and included the null when stratifying on histology. Using thiazides as active comparator yielded comparable results (OR, 1.34 [95% CI, 0.96\u20131.88]).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Use of high cumulative ACEI doses was associated with modestly increased odds of lung cancer although use of lower doses showed neutral associations. The established benefits of ACEIs should be considered when interpreting these findings.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circoutcomes.120.006687","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T10:36:42Z","timestamp":1610534202000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Use of ACE (Angiotensin-Converting Enzyme) Inhibitors and Risk of Lung Cancer"],"prefix":"10.1161","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6373-1386","authenticated-orcid":true,"given":"Kasper Bruun","family":"Kristensen","sequence":"first","affiliation":[{"name":"Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Denmark (K.B.K., A.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5730-9469","authenticated-orcid":true,"given":"Bl\u00e1naid","family":"Hicks","sequence":"additional","affiliation":[{"name":"Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University Belfast, United Kingdom (B.H.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-3556","authenticated-orcid":true,"given":"Laurent","family":"Azoulay","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health, Gerald Bronfman Department of Oncology, McGill University and Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada (L.A.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9314-5679","authenticated-orcid":true,"given":"Anton","family":"Potteg\u00e5rd","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Denmark (K.B.K., A.P.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.01.058"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4209"},{"key":"e_1_3_5_4_2","first-page":"124","article-title":"The kinin system\u2013bradykinin: biological effects and clinical implications. Multiple role of the kinin system\u2013bradykinin.","volume":"11","author":"Golias Ch","year":"2007","unstructured":"Golias, Ch, Charalabopoulos, A, Stagikas, D, Charalabopoulos, K, Batistatou, A. The kinin system\u2013bradykinin: biological effects and clinical implications. Multiple role of the kinin system\u2013bradykinin. Hippokratia. 2007;11:124\u2013128.","journal-title":"Hippokratia"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00726-014-1736-9"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-014-9930-3"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw213"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/1403494810393562"},{"key":"e_1_3_5_9_2","unstructured":"Friis S J\u00f8rgensen T Mellemkj\u00e6r L Olsen JH. Validation of The Danish Cancer Registry and selected Clinical Cancer Databases. 2012. Available from: https:\/\/sundhedsdatastyrelsen.dk\/da\/registre-og-services\/om-de-nationale-sundhedsregistre\/sygedomme-laegemidler-og-behandlinger\/cancerregisteret. Accessed March 12 2020."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S91125"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3079"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000221"},{"key":"e_1_3_5_13_2","volume-title":"Guidelines for ATC Classification and DDD Assignment 2019","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2018","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment 2019. World Health Organization. 2018."},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4145"},{"key":"e_1_3_5_15_2","volume-title":"International Classification of Diseases for Oncology","author":"Fritz A","year":"2013","unstructured":"Fritz, A, Percy, C, Jack, A, Shanmugaratnam, K, Sobin, L, Parkin, DM, Whelan, S (Eds.) International Classification of Diseases for Oncology. 3rd ed. First Revision. Geneva: World Health Organization; 2013.","edition":"3"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050893"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.007336"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2697"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011101)92:9<2462::aid-cncr1596>3.0.co;2-l"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04170.x"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.1908"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3977"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70106-6"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70260-6"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.23.4.439"},{"key":"e_1_3_5_28_2","first-page":"24","article-title":"Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity.","volume":"52","author":"Bunn PA","year":"1992","unstructured":"Bunn, PA, Jr, Chan, D, Dienhart, DG, Tolley, R, Tagawa, M, Jewett, PB. Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Res. 1992;52:24\u201331.","journal-title":"Cancer Res"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.87.318"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612033454171"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2009.21"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1200"},{"key":"e_1_3_5_33_2","unstructured":"Kampmann JP Thirstrup S. Angiotensin II antagonister: Sj\u00e6ldent indiceret. 2000. Available from: https:\/\/www.sst.dk\/da\/rationel-farmakoterapi\/maanedsbladet\/2000\/~\/media\/1986B497427611090191BB9488D7509C.ashx. Accessed March 12 2020."},{"key":"e_1_3_5_34_2","unstructured":"Elung-Jensen T Feldt-Rasmussen B. ACE-h\u00e6mmere vs. AT-II-antagonister \u2212 hvilken behandling skal man v\u00e6lge? 2004. Available from: https:\/\/www.sst.dk\/da\/rationel-farmakoterapi\/maanedsbladet\/2004\/~\/media\/DE71FF9583E2168A23519F163F9C1D18.ashx. Accessed March 12 2020."},{"key":"e_1_3_5_35_2","unstructured":"FDA medical review: NDA 207620 LCZ696 (Entresto) Novartis. 2015. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/207620Orig1s000MedR.pdf. Accessed March 12 2020."},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328344a7de"},{"key":"e_1_3_5_37_2","unstructured":"Based on calculations of data from the Danish online drug use statistics medstat.dk. Available from: http:\/\/www.medstat.dk\/. Accessed March 12 2020."},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k3851"}],"container-title":["Circulation: Cardiovascular Quality and Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCOUTCOMES.120.006687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T03:37:26Z","timestamp":1715571446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCOUTCOMES.120.006687"}},"subtitle":["A Nationwide Nested Case-Control Study"],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1161\/CIRCOUTCOMES.120.006687"],"URL":"https:\/\/doi.org\/10.1161\/circoutcomes.120.006687","relation":{},"ISSN":["1941-7713","1941-7705"],"issn-type":[{"value":"1941-7713","type":"print"},{"value":"1941-7705","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"2020-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e006687"}}